Patent · US Expired

Substituted pyrazoles as p38 kinase inhibitors

US7071198B1 · kind B1 · utility

2Cited by

0References

7Claims

0Family size

Assignee

Pharmacia Corporation · SE

Inventors

Ashok S. Naraian · Ballwin, US
Michael Clare · Skokie, US
Paul W. Collins · Deerfield, US
Joyce Z. Crich · Glenview, US
Rajesh Devraj · Chesterfield, US
Daniel L. Flynn · Lawrence, US
Lifeng Geng · Skokie, US
Matthew J. Graneto · Chesterfield, US
Cathleen Hanau · Chesterfield, US
Gunnar J. Hanson · Cambridge, US
Susan J. Hartmann · Kirkwood, US
Michael Hepperle · Boston, US
He Huang · Northbrook, US
Ish Khanna · Vernon Hills, US
Francis J. Koszyk · Prospect Heights, US
Shuyuan Liao · Northbrook, US
Suzanne Metz · Chesterfield, US
Win Naing · Chesterfield, US
Richard A. Partis · Evanston, US
Thao Perry · San Jose, US
Shashidhar N. Rao · Chesterfield, US
Shaun Raj Selness · Chesterfield, US
Michael S. South · Chesterfield, US
Michael A. Stealey · Libertyville, US
John J. Talley · Chesterfield, US
Michael L. Vazquez · Saint Louis, US
John Walker · Maryland Heights, US
Richard M. Weier · Lake Bluff, US
Xiangdong Xu · Gurnee, US
Syaulan Yang · Zhubeikou, TW

Key dates

Filing date	May 5, 2004
Grant date	Jul 4, 2006
Priority date	—
Expiry date	Apr 7, 2025

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D495/04
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.